{
    "clinical_study": {
        "@rank": "131348", 
        "arm_group": {
            "arm_group_label": "Arm I", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive dolastatin 10 IV over 10 minutes. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of dolastatin 10 in treating patients who have\n      recurrent or metastatic soft tissue sarcoma. Drugs used in chemotherapy use different ways\n      to stop tumor cells from dividing so they stop growing or die."
        }, 
        "brief_title": "Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma", 
        "condition": [
            "Ovarian Cancer", 
            "Sarcoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ovarian Neoplasms", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the response rate in patients with recurrent or metastatic soft tissue sarcomas\n      treated with dolastatin 10.\n\n      II. Determine the toxicity of this regimen in this patient population.\n\n      OUTLINE: This is an open label, multicenter study. Patients are stratified according to\n      center, prior therapy, histologic subtype, stage of disease at diagnosis, and current status\n      of disease (recurrent vs metastatic).\n\n      Patients receive dolastatin 10 IV over 10 minutes. Treatment repeats every 21 days in the\n      absence of disease progression or unacceptable toxicity.\n\n      Patients are followed at 1 month."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically proven recurrent or metastatic soft tissue sarcoma\n\n          -  No rhabdomyosarcoma, Ewing's sarcoma, chondrosarcoma, osteogenic sarcoma,\n             mesothelioma, or Kaposi's sarcoma Bidimensionally measurable disease other than\n             previously irradiated disease site(s) even if there has been progression within the\n             radiation field\n\n          -  Pulmonary nodule(s) at least 1 x 1 cm No brain metastases\n\n        PATIENT CHARACTERISTICS:\n\n          -  Age: 18 and over\n\n          -  Performance status: ECOG 0 or 1\n\n          -  Absolute neutrophil count at least 2,000/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  AST and ALT less than 1.5 times upper limit of normal (ULN) (3 times ULN if liver\n             metastases present)\n\n          -  Creatinine no greater than 1.5 mg/dL\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception during and for 3 months after study\n\n          -  No uncontrolled infection\n\n          -  No history of prior malignancy within the past 5 years except basal cell or squamous\n             cell skin cancer, carcinoma in situ of the cervix, or any other malignancy in\n             complete remission\n\n        PRIOR CONCURRENT THERAPY:\n\n          -  No more than 1 prior chemotherapy regimen in the adjuvant setting\n\n          -  No prior chemotherapy for metastatic disease\n\n          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)\n\n          -  At least 4 weeks since prior radiotherapy\n\n          -  Recovered from prior surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003778", 
            "org_study_id": "NCI-2012-02295", 
            "secondary_id": [
                "FCCC-98019", 
                "NCI-T98-0026", 
                "CDR0000066907"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Arm I", 
            "intervention_name": "dolastatin 10", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Dolastatin 10"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "recurrent adult soft tissue sarcoma", 
            "stage IV uterine sarcoma", 
            "recurrent uterine sarcoma", 
            "ovarian sarcoma", 
            "stage IV adult soft tissue sarcoma"
        ], 
        "lastchanged_date": "February 7, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/FCCC-98019"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80262"
                    }, 
                    "name": "University of Colorado Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Arthur G. James Cancer Hospital - Ohio State University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111"
                    }, 
                    "name": "Fox Chase Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of Dolastatin-10 in Patients With Previously Untreated Recurrent/Metastatic Sarcoma", 
        "overall_official": {
            "affiliation": "Fox Chase Cancer Center", 
            "last_name": "Margaret von Mehren, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2000", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003778"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 1999", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2000"
    }, 
    "geocoordinates": {
        "Arthur G. James Cancer Hospital - Ohio State University": "39.961 -82.999", 
        "Fox Chase Cancer Center": "39.952 -75.164", 
        "Mayo Clinic Cancer Center": "44.022 -92.47", 
        "University of Colorado Cancer Center": "39.739 -104.985"
    }
}